LumiraDx Ltd executed a non-binding letter of intent to acquire CA Healthcare Acquisition Corp. (NasdaqCM:CAHC) from CA Healthcare Sponsor LLC and others in a reverse merger transaction on February 5, 2021. LumiraDx Ltd entered into a definitive merger agreement to acquire CA Healthcare Acquisition Corp. from CA Healthcare Sponsor LLC and others in a reverse merger transaction on April 6, 2021. LumiraDx Ltd entered into a revised agreement to acquire CA Healthcare Acquisition Corp. on August 20, 2021. All current LumiraDx shareholders will retain the entirety of their existing holdings in the combined company. Post-acquisition, LumiraDx will hold 97.1%, CA Healthcare public investors will hold 2.2% and CAHC Sponsor shares will hold 0.6% stake in combined company. In a related transaction, LumiraDx also secured two new financing commitments totaling $400 million. BioPharma Credit PLC and its subsidiaries provided a $300 million loan to LumiraDx. In addition, Capital One, National Association has committed $100 million on an asset-based revolving credit facility. Upon closing of the transaction, LumiraDx and its common shares are expected to trade on Nasdaq under the ticker symbol "LMDX." The combined company will be led by existing CEO Ron Zwanziger and the other Co-Founders, and LumiraDx's existing board and governance principles will not change.

The transaction is subject to approval by the shareholders of each of CAHC and LumiraDx, the effectiveness of the Registration Statement, the approval for listing of the common shares and warrants of LumiraDx to be issued in connection with the Closing on Nasdaq, subject only to official notice of issuance, CAH will have at least $5,000,001 of net tangible assets following the exercise of redemption rights in accordance with CAH's organizational documents, LumiraDx also has the right to not consummate the Merger in the event that, as of the Effective Time, after giving effect to the exercise of redemption rights by any CAH stockholders, funds in the CAH trust account do not equal at least $65 million prior to payment of any unpaid or contingent liabilities, deferred underwriting fees or transaction costs of any of the parties, A&R Warrant Agreement, LumiraDx shall have delivered to CAH the PCAOB Audited Financials and satisfaction of customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both LumiraDx and CA Healthcare Acquisition Corp. The transaction is currently expected to close late Q2, early Q3 this year. As of August 20, 2021, the transaction is is currently expected to close in the fall of this year. On September 3, 2021, CA Healthcare filed a definitive proxy relating to the proposed business combination. As of September 7, 2021, it is announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective LumiraDx's registration statement on Form F-4. The Special Meeting to approve the pending business combination is to be held on September 28, 2021. As of September 23, 2021, CA Healthcare Sponsor LLC and Senvest Management, LLC on behalf of its advisory client, Senvest Master Fund, LP entered into a Non-Redemption Agreement. Post completion of the merger, CAH being the surviving corporation and a wholly-owned subsidiary of LumiraDx, shall convert into an equal amount of CAH Class A Common Stock, and upon consummation of the Merger shall be automatically canceled and extinguished and reissued to LumiraDx as one share of Common Stock of the surviving corporation, in consideration for the right to receive common shares of LumiraDx.

Evercore Group, LLC and Raymond James & Associates, Inc. acted as financial advisors to LumiraDx. Ian Lopez, Warren S. de Wied, Alan S. Kaden, Joseph E. Fox, Nick Thornton, Jason R. Ertel and Neil Caddy of Fried, Frank, Harris, Shriver & Jacobson LLP, Ian Lopez of Fried, Frank, Harris, Shriver & Jacobson (London) LLP and Edwin O'Connor, Paul Rosie, Kathryn Weston, Laurie Burlingame, Owen Remeika, Jocelyn Arel, Mike Patrone, Duncan Greenhalgh, Megan Gustafson, Andy Barton, Andre Amorim, Stephanie Philbin, Sarah Wicks, Elena Hera and Paul Schwartz of Goodwin Procter LLP acted as legal advisors to LumiraDx. BTIG, LLC acted as financial advisor and Alex Temel, Josh DuClos, David Ni, Dan Rawner, Albertina Kawatu, Patrick Harrison, Karen Kazmerzak, Stacy Crosnicker, Peter McCorkell, Bethany Wise, Torrey Cope, Marie Manley, Diane McEnroe, Helen Middleton, Rachael Hunt, Donielle McCutcheon, Tom Cunningham, William Long, Chris Brause, Rachel Kleinberg, Jennifer Coplan, Lauren Grau, Jim Ducayet and Michael Mann of Sidley Austin LLP acted as legal advisors to CA Healthcare Acquisition and CA Healthcare Sponsor LLC. Francis Wolf and Margaret Villani of Continental Stock Transfer & Trust Company acted as transfer agent for CA Healthcare. CA Healthcare has hired Morrow Sodali to assist in the proxy solicitation process for a fee of $30,000.